Pancreatic Cancer Research

ResearcherVeterans Health AdministrationActive in the last 2 years

Ganji Purnachandra Nagaraju

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-4989-5234; OpenAlex author ID A5060577741. Sources: OpenAlex.

Their work

Papers
41 (first author 5, last author 11)
Trials
0
Grants
0
Labs led
2
Collaborators
66
Papers, trials and grants by year

2012: 1 paper · 2013: 1 paper · 2014: 2 papers · 2015: 1 paper · 2016: 2 papers · 2017: 1 paper · 2018: 1 paper · 2019: 4 papers · 2020: 3 papers · 2021: 1 paper · 2022: 3 papers · 2023: 4 papers · 2024: 2 papers · 2025: 8 papers · 2026: 7 papers

Papers 41

  1. Mapping cellular heterogeneity and dynamic interactions in pancreatic cancer. Co-author DOI 10.1016/j.jconrel.2026.114757↗
  2. Pancreatic ductal adenocarcinoma: integrating molecular insights for targeted interventions. Co-author DOI 10.1038/s41392-026-02705-5↗
  3. Variable efficacy of the non-covalent KRAS G12D inhibitor (MRTX-1133) with obesity in murine pancreatic cancer. Co-author DOI 10.1038/s41698-026-01493-z↗
  4. Correction: Heat Shock Protein-90 Inhibition Alters Activation of Pancreatic Stellate Cells and Enhances the Efficacy of PD-1 Blockade in Pancreatic Cancer. Co-author DOI 10.1158/1535-7163.mct-26-0614↗
  5. Reprogramming the pancreatic ductal adenocarcinoma microenvironment: a novel integrin-targeted cytotoxin, ProAgio, potentiates chemotherapy. Co-author DOI 10.1186/s12943-026-02725-3↗
  6. ProAgio, a Novel Integrin αvβ3 Targeted Cytotoxin, Suppresses Tumor Growth and Reprograms the PDAC Microenvironment Co-author DOI 10.64898/2026.01.15.699725↗
  7. ADT-030, a novel PDE10 inhibitor, demonstrates potent antitumor activity in pancreatic ductal adenocarcinoma First author DOI 10.64898/2026.02.11.705411↗
  8. Role of YY1 in pancreatic ductal adenocarcinoma: Mechanisms and therapeutic perspectives. Last author DOI 10.1016/j.bbcan.2025.189415↗
  9. Paricalcitol plus hydroxychloroquine enhances gemcitabine activity and induces mesenchymal to epithelial transition in pancreatic ductal adenocarcinoma: A sing… Co-author DOI 10.1016/j.canlet.2025.217809↗
  10. Pancreatic cancer exosomes: Their role in drug resistance and immunomodulation. Last author DOI 10.1016/j.cytogfr.2025.10.004↗
  11. Polysaccharides as therapeutic vehicles in pancreatic cancer. Co-author DOI 10.1016/j.drudis.2025.104320↗
  12. Adiponectin: its role in diabetic and pancreatic cancer. Last author DOI 10.1016/j.mam.2025.101370↗
  13. Mechanism of enhancing chemotherapy efficacy in pancreatic ductal adenocarcinoma with paricalcitol and hydroxychloroquine. Co-author DOI 10.1016/j.xcrm.2024.101881↗
  14. Paricalcitol and hydroxychloroquine modulates extracellular matrix and enhance chemotherapy efficacy in pancreatic cancer. Co-author DOI 10.1038/s41417-025-00967-9↗
  15. ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic ductal adenocarcinoma. First author DOI 10.1186/s12943-025-02288-9↗
  16. Breaking the stromal barrier in pancreatic cancer: Advances and challenges. Last author DOI 10.1016/j.bbcan.2023.189065↗
  17. Small molecular inhibitors: Therapeutic strategies for pancreatic cancer. Last author DOI 10.1016/j.drudis.2024.104053↗
  18. Gemcitabine effects on tumor microenvironment of pancreatic ductal adenocarcinoma: Special focus on resistance mechanisms and metronomic therapies. First author DOI 10.1016/j.canlet.2023.216382↗
  19. Targeting the metabolism and immune system in pancreatic ductal adenocarcinoma: Insights and future directions. Co-author DOI 10.1016/j.cytogfr.2023.06.006↗
  20. Understanding the molecular mechanisms that regulate pancreatic cancer stem cell formation, stemness and chemoresistance: A brief overview. Co-author DOI 10.1016/j.semcancer.2022.12.004↗
  21. Obesity associated pancreatic ductal adenocarcinoma: Therapeutic challenges. Last author DOI 10.1016/j.semcancer.2023.11.002↗
  22. Fibroblast heterogeneity in pancreatic ductal adenocarcinoma: Perspectives in immunotherapy. Co-author DOI 10.1016/j.cytogfr.2022.09.001↗
  23. Targeting the tumor microenvironment of pancreatic ductal adenocarcinoma using nano-phytomedicines. Co-author DOI 10.1016/j.semcancer.2021.06.014↗
  24. Contemporary clinical trials in pancreatic cancer immunotherapy targeting PD-1 and PD-L1. Co-author DOI 10.1016/j.semcancer.2021.11.003↗
  25. Heat Shock Protein-90 Inhibition Alters Activation of Pancreatic Stellate Cells and Enhances the Efficacy of PD-1 Blockade in Pancreatic Cancer. Co-author DOI 10.1158/1535-7163.mct-19-0911↗
  26. HIF-1α and RKIP: a computational approach for pancreatic cancer therapy. Last author DOI 10.1007/s11010-020-03788-6↗
  27. Exosomes as therapeutic solutions for pancreatic cancer. First author DOI 10.1016/j.drudis.2020.09.037↗
  28. Resveratrol binds and inhibits transcription factor HIF-1α in pancreatic cancer. Last author DOI 10.1016/j.yexcr.2020.112126↗
  29. Curcumin analogs: Their roles in pancreatic cancer growth and metastasis. Co-author DOI 10.1002/ijc.31867↗
  30. Inhibition of HSP90 overcomes resistance to chemotherapy and radiotherapy in pancreatic cancer. Co-author DOI 10.1002/ijc.32227↗
  31. Small molecule tyrosine kinase inhibitors and pancreatic cancer-Trials and troubles. Last author DOI 10.1016/j.semcancer.2018.09.011↗
  32. DNA Fingerprint Technology: Its Application in Detecting Pancreatic Cancer. Last author DOI 10.1615/critrevoncog.2019031603↗
  33. Investigational agents to enhance the efficacy of chemotherapy or radiation in pancreatic cancer. Co-author DOI 10.1016/j.critrevonc.2018.03.016↗
  34. Inhibiting heat shock protein 90 and the ubiquitin-proteasome pathway impairs metabolic homeostasis and leads to cell death in human pancreatic cancer cells. Last author DOI 10.1002/cncr.30944↗
  35. Targeting the Janus-activated kinase-2-STAT3 signalling pathway in pancreatic cancer using the HSP90 inhibitor ganetespib. Co-author DOI 10.1016/j.ejca.2015.10.057↗
  36. Small molecule tolfenamic acid and dietary spice curcumin treatment enhances antiproliferative effect in pancreatic cancer cells via suppressing Sp1, disruptin… Co-author DOI 10.1016/j.jnutbio.2016.01.003↗
  37. Antiangiogenic effects of a novel synthetic curcumin analogue in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2014.12.007↗
  38. Imaging and curcumin delivery in pancreatic cancer cell lines using PEGylated α-Gd2(MoO4)3 mesoporous particles. Co-author DOI 10.1039/c3dt52692e↗
  39. CHD7 expression predicts survival outcomes in patients with resected pancreatic cancer. Co-author DOI 10.1158/0008-5472.can-13-1996↗
  40. Novel synthetic curcumin analogues EF31 and UBS109 are potent DNA hypomethylating agents in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2013.08.002↗
  41. Developing histone deacetylase inhibitors in the therapeutic armamentarium of pancreatic adenocarcinoma. First author DOI 10.1517/14728222.2012.691473↗

Closest collaborators

The 25 strongest of 66 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Bassel F. El‐Rayes · 25 shared papers, 2012–2026 · strength 4.09
  2. Sujith Sarvesh · 9 shared papers, 2023–2026 · strength 2.21
  3. Dhana Sekhar Reddy Bandi · 9 shared papers, 2023–2026 · strength 2.21
  4. Jeremy B. Foote · 8 shared papers, 2023–2026 · strength 1.96
  5. Mehmet Akce · 7 shared papers, 2025–2026 · strength 1.70
  6. Batoul Farran · 7 shared papers, 2019–2026 · strength 1.69
  7. Seema Kumari · 5 shared papers, 2024–2026 · strength 1.60
  8. Mundla Srilatha · 5 shared papers, 2023–2026 · strength 1.58
  9. Rama Rao Malla · 3 shared papers, 2022–2025 · strength 0.89
  10. Gregory B. Lesinski · 5 shared papers, 2017–2026 · strength 0.74
  11. Ashiq Masood · 3 shared papers, 2025–2026 · strength 0.73
  12. Yuvasri Golivi · 3 shared papers, 2022–2025 · strength 0.68
  13. Karina Jin Yoon · 3 shared papers, 2025–2026 · strength 0.65
  14. Zhi-Ren Liu · 2 shared papers, 2026 · strength 0.56
  15. Bala Prabhakar Girish · 2 shared papers, 2022–2025 · strength 0.53
  16. Tha Luong · 2 shared papers, 2022–2023 · strength 0.49
  17. Matthew R. Farren · 3 shared papers, 2017–2026 · strength 0.43
  18. Yulia Y. Maxuitenko · 2 shared papers, 2025–2026 · strength 0.41
  19. Donald J Buchsbaum · 2 shared papers, 2025–2026 · strength 0.41
  20. Adam B. Keeton · 2 shared papers, 2025–2026 · strength 0.41
  21. Gary Anthony Piazza · 2 shared papers, 2025–2026 · strength 0.41
  22. Asfar Sohail Azmi · 2 shared papers, 2025–2026 · strength 0.41
  23. Shishir Kumar Maithel · 3 shared papers, 2014–2026 · strength 0.39
  24. Jay Z. Natu · 1 shared paper, 2023 · strength 0.39
  25. Upender Manne · 2 shared papers, 2025 · strength 0.38

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.